NCT03602430

Cholecalciferol on Hemodialysis Patients

Effect of Cholecalciferol on Hemodialysis Patients

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

* Screening the prevalence of vitamin D deficiency among Egyptian hemodialysis patients on a single center (Ain Shams University hospital). * Assessing the effect of the native type of vitamin D (Cholecalciferol) on replenishing its deficiency via extra-renal vitamin D receptors (VDR), among Egyptian hemodialysis patients. * Assessing the effect of cholecalciferol on vascular calcification among Egyptian hemodialysis patients. * Assessing the effect of cholecalciferol on Blood pressure, parathyroid hormone.

Conditions

• Hemodialysis Complication
• Vitamin D Deficiency
• Vascular Calcification

Interventions

Type	Name	Description
DRUG	Cholecalciferol	Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
DRUG	Placebo	A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.

Timeline

• Start date: 2018-07-01
• Primary completion: 2018-09-15
• Completion: 2018-09-28
• First posted: 2018-07-26
• Last updated: 2019-01-09

Locations

1 site across 1 country: Egypt